NCI IMAT R61 & R33
Supports translational cancer technology from concept proof to advanced development through NCI.
The NCI Innovative Molecular Analysis Technologies (IMAT) program funds early-stage development of novel analytical technologies for cancer research, issued as paired R61 and R33 mechanisms under annual RFAs by NCI's Center for Strategic Scientific Initiatives. The FY25 cycle comprised four RFAs: RFA-CA-25-001 (R61 for molecular and cellular analysis technologies), RFA-CA-25-002 (R33 for advanced …
Molecular and cellular analysis technologies; biospecimen science technologies for basic and clinical cancer research.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Guides for this application
All guides →NIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Start hereTRL Levels Explained for Deeptech Founders
Learn what TRL levels mean, how to estimate technology readiness, and how TRL affects grants, EIC Accelerator, SBIR/STTR, funding stage, and application evidence.
More from NCI
All grants from this funder →Childhood, Adolescent and Young Adult (AYA) Cancer Data Innovation Challenge — Track 1
🇺🇸NCI · United States
Pays entities up to $566,665 across three milestones to add shovel-ready cancer data or tools to NCI's CCDI ecosystem.
NCI SBIR/STTR Omnibus (Next Receipt 5)
🇺🇸NCI · United States
Supports small businesses developing cancer technologies through national NIH collaboration pathways.
NCI Bioengineering Research Grants (BRG)
🇺🇸NCI · United States
Supports bioengineering teams tackling cancer by connecting life and physical science groups.
Cancer Grand Challenges
🇺🇸NCI · United States
Supports large interdisciplinary global teams tackling transformative unsolved problems in cancer biology.
NCI Small Grants Program — R03
🇺🇸NCI · United States
Supports cancer pilot research with broad domestic and international eligibility.
Similar grants
Browse the directory →
NCATS STTR Phase I
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to conduct feasibility studies on translational science innovations toward commercialization.
NCATS SBIR Phase I
🇺🇸NCATS · United States
Supports small businesses testing translational science tools and technologies through early feasibility and commercialization groundwork.
NSF SBIR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups demonstrating scientific feasibility of novel science and engineering innovations.
NSF STTR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups partnering with nonprofit research institutions for early-stage feasibility studies.
NIH SBIR Phase I
🇺🇸NIH SEED · United States
Funds early stage United States biomedical teams through NIH seed support for feasibility work on prototype ready ideas.
NIH SBIR Phase I (Omnibus)
🇺🇸NIH · United States
Funds United States small businesses advancing biomedical and behavioral-health innovations through early technical validation.